Educational reference only. Not medical advice. Nothing on this site is for sale.
Latest
CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyTrial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialFDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesCompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeTrial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMTrial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetTrial resultFull TRIUMPH-2 retatrutide results published in The LancetFDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesWADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances
Sign in

Longevity & mitochondrial

Bronchogen

Also called AEDL peptide, Ala-Glu-Asp-Leu, bronchial peptide bioregulator

Bronchogen is a tiny lab-made peptide, four amino acids long, from the Russian 'peptide bioregulator' program led by Vladimir Khavinson. It is promoted as a helper for the lining of the airways (bronchi). The evidence is almost all cell and rat studies from one research group, and it is not an approved medicine in the US or Europe.

Preclinical onlyStudied in cells or animals only. Effects in people are unknown.

All printable flashcards

Illustrative chain. The exact sequence has not been published in a source we could verify.

Overview

Bronchogen is a tiny lab-made peptide, four amino acids long, from the Russian 'peptide bioregulator' program led by Vladimir Khavinson. It is promoted as a helper for the lining of the airways (bronchi). The evidence is almost all cell and rat studies from one research group, and it is not an approved medicine in the US or Europe.

How it works

Proposed, not established. The developers suggest that very short peptides enter cell nuclei, bind DNA or histone proteins, and switch on genes typical of the tissue they are named for (an 'epigenetic' effect). In human embryonic bronchial cell cultures the peptide changed levels of proliferation and differentiation markers (for example NKX2-1, FOXA1/2, MUC4, MUC5AC, surfactant protein A), and test-tube work suggested it binds DNA 3. These are lab findings from the developing group; no confirmed receptor or human mechanism exists.

What research shows

  • Cell study (human embryonic bronchial epithelium, early vs. late passages): the peptide shifted proliferation markers and raised expression of airway differentiation genes, with the strongest effect in 'aged' cultures (Khavinson et al., 2014) 3.
  • Cell study: in aging human bronchial epithelial cultures it increased differentiation-factor expression (Khavinson et al., 2012) 2.
  • Rat study: in a nitrogen-dioxide model of COPD, one month of Bronchogen was reported to reduce airway-lining remodeling and inflammatory cell markers (Kuzubova et al., 2015) 4.
  • A 2020 review by the developers says it has been used in COPD and chronic bronchitis patients, but gives no trial sizes or data 5; no controlled human trial was found in this review.
  • Nearly all published work comes from Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology and its collaborators; independent replication is scarce.

Doses studied in people

No published controlled human trial with a verifiable dose was found; doses circulating online are not trial-derived.

Read this first: these are the amounts given to participants in published studies or written on official prescribing labels, reported for reference. They are not recommendations. Trial doses were chosen for specific patients under medical supervision, and a dose that is safe in one person can be harmful in another.

Vial math

Many research vials hold 5 or 10 mg of powder. This table shows how much ends up in each mark on a U-100 insulin syringe for common amounts of added liquid. It is arithmetic only, not a dose.

VialLiquid addedConcentrationPer unit (0.01 mL)
5 mg1 mL5 mg/mL50 mcgOpen in calculator
5 mg2 mL2.5 mg/mL25 mcgOpen in calculator
5 mg3 mL1.67 mg/mL16.7 mcgOpen in calculator
10 mg1 mL10 mg/mL100 mcgOpen in calculator
10 mg2 mL5 mg/mL50 mcgOpen in calculator
10 mg3 mL3.33 mg/mL33.3 mcgOpen in calculator

More sizes: all vial sizes · How this works: Syringes and units · Reconstitution guide.

Safety

  • No formal human safety studies have been published; long-term safety is unknown.
  • Unregulated 'research' products may vary in purity, sequence and content.

Report side effects of any drug or product to the FDA through MedWatch. For a possible poisoning in the US, call Poison Control at 1-800-222-1222.

History

Created at the St. Petersburg Institute of Bioregulation and Gerontology as part of Khavinson's series of organ-named synthetic short peptides, which followed earlier animal-tissue extracts such as thymalin and epithalamin 1. Papers on it appear from about 2011 onward 923.

Common questions

Is Bronchogen an approved medicine?

No. It is not FDA-approved and is not on FDA's lists of substances under review for compounding 7.

What does the evidence show?

Mostly cell-culture and rat studies from the group that created it, such as changes in airway-cell genes and less airway damage in a rat COPD model 34. Controlled human trials have not been published.

Is Bronchogen banned in sport?

It is not named on WADA's 2026 list, but unapproved substances generally fall under the S0 'prohibited at all times' rule 8.

What are the known risks?

Human safety has not been formally studied, so long-term risks are unknown, and products sold as 'research chemicals' are unregulated.

Related compounds

Longevity & mitochondrialPreclinical onlyFlashcard

Chonluten

Khonluten · Honluten

Chonluten is a very short lab-made peptide (three amino acids) from Vladimir Khavinson's Russian 'peptide bioregulator' series, aimed at the lungs and airways.

Immune & antimicrobialEarly human dataFlashcard

Vilon

KE dipeptide · Lys-Glu

Vilon is the smallest of Vladimir Khavinson's Russian 'peptide bioregulators': just two amino acids (lysine and glutamic acid).

Longevity & mitochondrialPreclinical onlyFlashcard

Epitalon

epithalon · epithalone

Epitalon is a tiny four-amino-acid peptide made in the lab, modeled on an extract from the pineal gland.

Sources

  1. Khavinson VKh. Peptides, genome, aging. Advances in Gerontology 2014;4(4):337–345 (developer's review; Table 1 lists names, sequences and masses) Journal
  2. Khavinson VKh et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med 2012;153:148–151 Journal
  3. Khavinson VKh et al. Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium. Lung 2014;192(5):781–791 Journal
  4. Kuzubova NA et al. Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bull Exp Biol Med 2015;159:685–688 Journal
  5. Khavinson V et al. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules 2020;25(19):4389 PubMed review
  6. Khavinson VKh et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 PubMed review
  7. FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026) Regulatory
  8. WADA 2026 Prohibited List (official English text, Dutch Treaty Series Trb. 2026, 25) Regulatory
  9. Effect of the Peptide Bronchogen (Ala-Asp-Glu-Leu) on DNA Thermostability. Bull Exp Biol Med 2011 Journal

Last reviewed 2026-10-26 · How we research · Found an error? See our corrections policy.